Detalhe da pesquisa
1.
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
Blood
; 142(19): 1647-1657, 2023 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37441846
2.
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Cancer
; 129(4): 560-568, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36458426
3.
Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure.
Am J Hematol
; 98(10): E281-E284, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37515433
4.
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
Am J Hematol
; 98(11): 1780-1790, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37665752
5.
Invasive mucorales sinusitis in a young patient with Emberger syndrome and newly diagnosed AML: A case report and literature review of invasive fungal infections in GATA2 deficiency.
Mycoses
; 66(12): 1029-1034, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37550272
6.
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
Acta Haematol
; 145(5): 529-536, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35717939
7.
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome.
Br J Haematol
; 195(3): 378-387, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34340254
8.
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Am J Hematol
; 95(11): 1399-1420, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32744763
9.
Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.
Hematol Oncol
; 37(1): 96-102, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30153704
10.
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS).
Am J Hematol
; 96(7): E246-E249, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33811786
11.
Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3).
Am J Hematol
; 95(12): E326-E329, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32886803
12.
Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms.
Cancer Med
; 13(5): e7093, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38497538
13.
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.
Clin Cancer Res
; 30(7): 1319-1326, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38300723
14.
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.
J Clin Oncol
; 42(13): 1499-1508, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38277619
15.
Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies.
Blood Adv
; 7(19): 5691-5697, 2023 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36696472
16.
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Leuk Lymphoma
; 63(13): 3154-3164, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36059252
17.
Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms.
Biology (Basel)
; 12(1)2022 Dec 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36671709
18.
Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.
Exp Hematol
; 115: 44-53, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36150563
19.
Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia.
Leuk Res
; 101: 106511, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33517186
20.
LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents.
Leuk Lymphoma
; 61(6): 1493-1499, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32036728